Core Viewpoint - Ambiq Micro, Inc. has announced the pricing of its upsized underwritten public offering of common stock at $31.00 per share, indicating strong market interest in its ultra-low-power semiconductor solutions for edge AI [1] Company Summary - Ambiq is offering a total of 2,679,600 shares, with 2,636,651 shares being offered by the company itself and 42,949 shares by certain stockholders [1] - The gross proceeds from this offering will significantly enhance Ambiq's financial position, supporting its growth in the semiconductor industry [1]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Tandem Diabetes securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. - A class action is being prepared by Rosen Law Firm to seek recovery of investor losses [2]. Group 2: Company Incident and Stock Impact - On August 7, 2025, Tandem Diabetes issued a press release regarding a voluntary medical device correction for select t:slim X2 insulin pumps, addressing a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering substantial amounts for clients [4].

On Thursday, Cathie Wood-led Ark Invest made significant trades involving Tempus AI Inc. (NASDAQ:TEM) , WeRide Inc. (NASDAQ:WRD) , and Roku Inc. (NASDAQ:ROKU) .The Tempus AI TradeArk Invest’s interest in Tempus AI was evident as both the ARK Genomic Revolution ETF (BATS:ARKG)  and ARK Innovation ETF (BATS:ARKK)  acquired a total of 13,532 shares. The purchase comes on the heels of Tempus AI’s impressive financial performance, with the company reporting a revenue surge of 83% year-over-year for 2025 in a pre ...

Core Insights - CACI International Inc is a key player in the information technology sector, specializing in services for government and commercial clients, particularly in defense, intelligence, and cybersecurity [1] - The company is competing with major firms like Leidos and Booz Allen Hamilton, offering a diverse range of IT services and solutions [1] Financial Performance - On January 22, 2026, a new price target of $800 was set for CACI by Tobey Sommer from Truist Financial, indicating a potential upside of 22.26% from the current stock price of $654.36 [2] - CACI's stock has experienced a positive trend, increasing by 3.45% or $21.80, reaching $654.36, with fluctuations between $622.05 and $661.99, the latter being the highest price in the past year [4] - The company has a market capitalization of approximately $14.45 billion and a trading volume of 595,707 shares, highlighting its significant presence in the market [5] Strategic Outlook - The Q2 2026 earnings call is a critical event for investors, providing insights into CACI's financial health and strategic plans, typically covering revenue growth, profit margins, and significant contracts [3] - The ability to secure substantial contracts and maintain a competitive edge in the IT sector is essential for CACI to achieve the $800 price target set by Truist Financial [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Varonis Systems, Inc. (NASDAQ: VRNS) common stock between February 4, 2025, and October 28, 2025, of the March 9, 2026, lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Varonis common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 9, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that Varonis made materially false and misleading statements regarding its ability to maintain Annual Recurring Revenue (ARR) projections while transitioning customers to a software-as-a-service (SaaS) model [5]. - It is claimed that Varonis was not adequately prepared to convince existing users of the benefits of the SaaS offering, leading to reduced ARR growth potential [5]. - The lawsuit asserts that the positive statements made by Varonis about its business and prospects were materially misleading, resulting in investor damages when the true information became public [5].

Core Viewpoint - Medaro Mining Corp. has granted stock options and restricted share rights to advisors and directors, while also fulfilling obligations related to a mineral claims acquisition in Ontario [1][3]. Group 1: Stock Options and Restricted Share Rights - The company has granted a total of 400,000 stock options and 170,000 restricted share rights to certain advisors and directors [1]. - The stock options will vest in three tranches: 33% after 4 months, 33% after 8 months, and the remaining 33% after 12 months, with an exercise price of C$0.39 per share [2]. - The restricted share rights will vest 100% after 4 months from the grant date [2]. Group 2: Mineral Claims Acquisition - Medaro Mining holds the option to acquire a 100% interest in the Clay Howells Project in Ontario, subject to a production royalty [4]. - To exercise this option, the company must make payments of $20,000 by August 13, 2026, $30,000 by August 13, 2027, and $38,000 by August 13, 2028 [5]. - If the option is exercised, the optionors will retain a 1.5% net smelter returns royalty, with the company having the right to purchase one-third of the royalty for a one-time payment of $500,000 [5]. Group 3: Securities and Compliance - All securities issued in connection with the stock options, restricted share rights, and consideration shares are subject to a statutory hold period of four months and one day under Canadian securities laws [6]. - Medaro Mining Corp. is a lithium exploration company based in Vancouver, BC, owning the James Bay Pontax Project and CYR South lithium properties in Quebec [7].

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Eastern Bankshares, Inc. (EBC) reported a revenue of $283.5 million for the quarter ended December 2025, marking a year-over-year increase of 25.6% and an EPS of $0.44 compared to $0.34 a year ago, indicating strong financial performance [1] - The revenue exceeded the Zacks Consensus Estimate of $282.41 million by 0.39%, while the EPS surpassed the consensus estimate of $0.41 by 7.32% [1] Financial Performance Metrics - The efficiency ratio (GAAP) was reported at 66.8%, higher than the average estimate of 59.2% based on three analysts [4] - The net interest margin stood at 3.6%, slightly above the average estimate of 3.5% from three analysts [4] - Total interest-earning assets averaged $26.74 billion, below the two-analyst average estimate of $27.39 billion [4] - Net interest income was $237.4 million, exceeding the average estimate of $235.79 million from three analysts [4] - Total noninterest income reached $46.1 million, surpassing the average estimate of $45.92 million from three analysts [4] - Service charges on deposit accounts were $9.9 million, below the average estimate of $12.99 million from two analysts [4] - Other income was reported at -$0.7 million, significantly lower than the average estimate of $5.03 million from two analysts [4] - Interest rate swap income was $1.4 million, exceeding the average estimate of $0.92 million from two analysts [4] - Card income reached $5.9 million, above the average estimate of $4.82 million from two analysts [4] - Investment advisory fees were reported at $18.6 million, slightly above the average estimate of $18.02 million from two analysts [4] Stock Performance - Shares of Eastern Bankshares have returned +8% over the past month, outperforming the Zacks S&P 500 composite's +0.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Corcept Therapeutics Incorporated (NASDAQ:CORT) is focused on developing medications that modulate cortisol effects to treat severe disorders, including oncologic conditions [1] - H.C. Wainwright upgraded CORT's stock to "Buy" and raised its price target from $90 to $105, with the stock priced at approximately $41.87 at the time of the announcement [1][5] Stock Performance - Following the upgrade, CORT's stock has seen a notable increase, currently priced at $41.30, reflecting a 13.74% increase with a change of $4.99 [3][5] - The stock has fluctuated between a low of $40.46 and a high of $52.84 during today's trading [3] - Over the past year, the stock reached a high of $117.33 and a low of $32.99 [3] Clinical Trial Results - The upgrade coincides with significant developments, particularly the successful results from the ROSELLA Phase 3 trial, which tested the combination of relacorilant and nab-paclitaxel for treating platinum-resistant ovarian cancer [2] - The trial demonstrated a 35% reduction in the risk of death for patients receiving the combination therapy [2][5] - The combination therapy was well-tolerated, with adverse events similar to those experienced with nab-paclitaxel monotherapy [4] Market Capitalization and Trading Volume - Corcept's market capitalization is approximately $4.34 billion, with a trading volume of 5,304,058 shares [4]

Core Viewpoint - SLB N.V. is a leading provider of technology and services in the energy industry, specializing in digital integration, reservoir performance, well construction, and production systems, competing with major players like Halliburton and Baker Hughes [1] Price Target Trends - The consensus price target for SLB has increased over the past year, rising from $49.13 last year to $50.48 last quarter, and reaching $51.20 last month, indicating growing analyst optimism [2] - Barclays analyst David Anderson has set a price target of $59 for SLB, reflecting strong confidence in the company's growth potential [2][4] Earnings and Market Performance - SLB is scheduled to release its fourth-quarter earnings on January 23, with investors closely monitoring the situation due to challenges from reduced demand for oilfield services [3] - Despite these challenges, SLB's stock has appreciated by approximately 16% over the past year, driven by geopolitical dynamics and global upstream expectations [3] - The company's strategic positioning in the energy sector is considered a key factor in its stock performance, with analysts suggesting that price targets may evolve as SLB continues to innovate and expand its offerings [4]